Financial reports
10-Q
2025 Q1
Quarterly report
12 Feb 25
ARS
2024 FY
Annual report to shareholders
21 Jan 25
10-K
2024 FY
Annual report
17 Dec 24
10-Q
2024 Q3
Quarterly report
14 Aug 24
10-Q
2024 Q2
Quarterly report
14 May 24
10-Q
2024 Q1
Quarterly report
13 Feb 24
ARS
2023 FY
Annual report to shareholders
29 Jan 24
10-K
2023 FY
Annual report
15 Dec 23
10-Q
2023 Q3
Quarterly report
14 Aug 23
10-Q
2023 Q2
Quarterly report
12 May 23
Current reports
8-K/A
Departure of Directors or Certain Officers
20 Feb 25
8-K
Submission of Matters to a Vote of Security Holders
14 Feb 25
8-K
NeuroOne® Reports First Quarter Fiscal Year 2025 Financial Results and Provides Corporate Update
12 Feb 25
8-K
Other Events
4 Feb 25
8-K
Regulation FD Disclosure
14 Jan 25
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
10 Jan 25
8-K
NeuroOne® Announces Preliminary Unaudited First Quarter Fiscal 2025 Revenue Increase to a Record $6.2 Million
10 Jan 25
8-K
Results of Operations and Financial Condition
17 Dec 24
8-K
Termination of a Material Definitive Agreement
8 Nov 24
8-K
NeuroOne® Announces Expansion of Existing Distribution Agreement with Zimmer Biomet for Commercialization of OneRF™ Ablation System
31 Oct 24
Registration and prospectus
S-8
Registration of securities for employees
21 Feb 25
S-3/A
Shelf registration (amended)
12 Sep 24
S-3
Shelf registration
30 Aug 24
424B5
Prospectus supplement for primary offering
16 Aug 24
D
$276.04 k in options / securities to be acquired, sold $276.04 k, 20 investors
16 Aug 24
S-3/A
Shelf registration (amended)
14 Aug 24
S-3
Shelf registration
31 May 24
S-8
Registration of securities for employees
31 Jan 24
424B5
Prospectus supplement for primary offering
5 Jan 24
S-8
Registration of securities for employees
15 Dec 23
Proxies
DEFA14A
Additional proxy soliciting materials
7 Feb 25
DEFA14A
Additional proxy soliciting materials
5 Feb 25
DEF 14A
Definitive proxy
21 Jan 25
PRER14A
Preliminary revised proxy
13 Jan 25
PRE 14A
Preliminary proxy
10 Jan 25
DEF 14A
Definitive proxy
29 Jan 24
DEF 14A
Definitive proxy
27 Jan 23
DEF 14A
Definitive proxy
29 Apr 22
DEF 14A
Definitive proxy
6 May 21
DEF 14A
Definitive proxy
1 May 20
Other
EFFECT
Notice of effectiveness
16 Sep 24
EFFECT
Notice of effectiveness
19 Aug 24
EFFECT
Notice of effectiveness
15 Jun 21
CORRESP
Correspondence with SEC
10 Jun 21
UPLOAD
Letter from SEC
9 Jun 21
CERT
Certification of approval for exchange listing
25 May 21
EFFECT
Notice of effectiveness
9 Mar 21
CORRESP
Correspondence with SEC
5 Mar 21
CORRESP
Correspondence with SEC
4 Mar 21
UPLOAD
Letter from SEC
19 Feb 21
Ownership
4
Steve Mertens
20 Feb 25
4
Mark Christianson
20 Feb 25
4
David A Rosa
20 Feb 25
4
PAUL BUCKMAN
19 Feb 25
4
Edward Andrle
19 Feb 25
4
JEFFREY S MATHIESEN
19 Feb 25
SC 13G/A
MANCHESTER MANAGEMENT CO LLC
14 Feb 25
SC 13G/A
MERCHANT ADVENTURE FUND, L.P.
4 Feb 25
4
Steve Mertens
4 Feb 25
4
Mark Christianson
4 Feb 25